Generex Biotechnology (OTCMKTS:GNBT) and Celsion (NASDAQ:CLSN) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their profitability, earnings, dividends, analyst recommendations, risk, valuation and institutional ownership.
This is a breakdown of current recommendations and price targets for Generex Biotechnology and Celsion, as provided by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
Risk & Volatility
Generex Biotechnology has a beta of -2.95, suggesting that its share price is 395% less volatile than the S&P 500. Comparatively, Celsion has a beta of 2.2, suggesting that its share price is 120% more volatile than the S&P 500.
This table compares Generex Biotechnology and Celsion’s net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
Insider and Institutional Ownership
5.5% of Celsion shares are held by institutional investors. 35.2% of Generex Biotechnology shares are held by insiders. Comparatively, 9.3% of Celsion shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.
Valuation and Earnings
This table compares Generex Biotechnology and Celsion’s gross revenue, earnings per share (EPS) and valuation.
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|Generex Biotechnology||$700,000.00||56.63||$36.33 million||N/A||N/A|
Generex Biotechnology has higher revenue and earnings than Celsion.
Generex Biotechnology beats Celsion on 6 of the 11 factors compared between the two stocks.
Generex Biotechnology Company Profile
Generex Biotechnology Corporation, through its subsidiaries, primarily engages in the administration of formulations of large molecule drugs to the oral cavity using a hand-held aerosol applicator in Canada and the United States. It offers Generex Oral-lyn, an insulin formulation administered as a fine spray into the oral cavity. The company is also developing AE37, a synthetic peptide vaccine to stimulate a potent and specific immune response against tumors with low levels of expression of the HER-2/neu oncogene in patients with breast cancer and prostate cancer. In addition, it develops, manufactures, and distributes rapid point-of-care in-vitro medical diagnostics for infectious diseases, such as human immunodeficiency virus, tuberculosis, malaria, hepatitis B, hepatitis C, syphilis, and others; and cassette devices. The company has a collaboration agreement with HydRx Farms Ltd. to co-develop products for the delivery of cannabinoids via the buccal mucosa. Generex Biotechnology Corporation was founded in 1983 and is based in Miramar, Florida.
Celsion Company Profile
Celsion Corporation, a development stage oncology drug company, focuses on the development and commercialization of directed chemotherapies, DNA-mediated immunotherapy, and RNA based therapies for the treatment of cancer. Its lead product candidate is ThermoDox, a liposomal encapsulation of doxorubicin that is in Phase III clinical trial for treating primary liver cancer. The company is also developing GEN-1, a DNA-based immunotherapeutic product for the localized treatment of ovarian and brain cancers. Celsion Corporation was founded in 1982 and is headquartered in Lawrenceville, New Jersey.
Receive News & Ratings for Generex Biotechnology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Generex Biotechnology and related companies with MarketBeat.com's FREE daily email newsletter.